NeuroPace (NPCE) Non-Current Deffered Revenue (2020 - 2021)
NeuroPace's (NPCE) quarterly Non-Current Deffered Revenue came in at $1.4 million in Q4 2021, up 7.61% year-on-year from $1.3 million in Q4 2020, and up 34.49% quarter-over-quarter from $1.0 million in Q3 2021.
NeuroPace (NPCE) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
NeuroPace's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- On a quarterly basis, Non-Current Deffered Revenue rose 7.61% year-over-year to $1.4 million in Q4 2021; TTM through Dec 2021 was $1.4 million, a 7.61% increase from a year earlier, with the FY2021 full-year figure at $1.4 million, up 7.61% from the prior year.
- Non-Current Deffered Revenue rose to $1.4 million in Q4 2021 per NPCE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $1.4 million in Q4 2021 and bottomed at $1.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 512.79 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 1.04 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 1.30 Mn |